RxDoctor Payments Data

Brian Snoddy, MD

Interventional Cardiology · Birmingham, ALNPI 1649355827

Payments from drug & device makers

$3,758in general payments, 2019–2025

Across 213 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$658
  • Boehringer Ingelheim$504
  • Abbott$463
  • Pfizer$382
  • E.r. Squibb & Sons, L.L.C.$283
  • Amgen$273
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,758 in reported general payments places this provider in the 25th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$380,755
Medicare patients
925
Services billed
3,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,055$796,907
FarxigaDapagliflozin Propanediol153$96,544
XareltoRivaroxaban93$83,527
JardianceEmpagliflozin104$71,053
EntrestoSacubitril/Valsartan101$66,032
Repatha SureclickEvolocumab80$55,333
MultaqDronedarone Hcl21$28,367
Metoprolol Succinate749$12,511
Telmisartan177$11,995
Ezetimibe268$9,371
BrilintaTicagrelor20$8,740
Rosuvastatin Calcium343$8,677
Atorvastatin Calcium449$7,573
Ranolazine ErRanolazine104$7,279
Flecainide Acetate129$7,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$382$796,9071,055 claims
AstraZenecaFarxiga, Brilinta$135$105,284173 claims
Johnson & JohnsonXarelto$162$83,52793 claims
Boehringer IngelheimJardiance$504$71,053104 claims
NovartisEntresto$658$66,032101 claims
Sanofi-aventis U.S. LLCMultaq$148$28,36721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →